基于小组干预减少慢性疼痛阿片类药物使用:一项随机临床试验
该多中心随机临床试验纳入608名因慢性非恶性疼痛而服用强阿片类药物的成人,比较小组自我管理干预与常规护理。12个月随访时,干预组停药比例29% vs 常规护理组7%(OR 5.55,95%CI 2.80-10.99),但PROMIS疼痛干扰评分组间差异无统计学意义(均差-0.52,95%CI -1.94至0.89,P=0.15)。
要点
- 小组自我管理干预组12个月阿片停药率29%,常规护理组7%(OR 5.55,95%CI 2.80-10.99)。
- PROMIS疼痛干扰评分两组差异无统计学意义(均差-0.52,95%CI -1.94至0.89,P=0.15)。
- 干预组严重不良事件发生率8%,常规护理组5%。
核心结论
- 在因非恶性原因导致慢性疼痛的人群中,与常规护理相比,包含小组和个体支持及技能学习的小组教育干预显著减少了患者报告的阿片类药物使用,但对感知的疼痛干扰日常生活活动无影响。
研究设计与样本
- 多中心随机临床试验,纳入608名服用强阿片类药物(丁丙诺啡、二苯哌己酮、吗啡、二乙酰吗啡、芬太尼、氢吗啡酮、美沙酮、羟考酮、阿片全碱、喷他佐辛、哌替啶、他喷他多和曲马多)治疗慢性非恶性疼痛的成人。
- 研究于2017年5月17日至2019年1月30日在英格兰191家初级保健中心开展,最终随访于2020年3月18日进行。
- 参与者按1:1随机分配至常规护理组或为期3天的小组课程(强调技能学习和教育),并辅以为期12个月由护士和非专业人员提供的一对一支持。
主要发现
- 608名随机参与者(平均年龄61岁;女性362名[60%];每日吗啡等效剂量中位数46 mg [IQR 25至79])中,440名(72%)完成了12个月随访。
- 12个月随访时,PROMIS-PI-SF-8a评分在干预组为-4.1,常规护理组为-3.17,组间均差-0.52(95%CI -1.94至0.89;P=0.15),差异无统计学意义。
- 12个月时,干预组225名参与者中65名(29%)停用阿片类药物,常规护理组208名中15名(7%)停用(比值比5.55 [95%CI 2.80至10.99];绝对差异21.7% [95%CI 14.8%至28.6%];P<.001)。
- 干预组严重不良事件发生率为8%(25/305),常规护理组为5%(16/303);最常见严重不良事件为胃肠道事件(干预组2%,常规护理组0%)和运动/肌肉骨骼事件(干预组2%,常规护理组1%)。
- 干预组4人(1%)因可能的阿片戒断症状(气短、潮热、发热和疼痛、小肠出血、过量自杀未遂)接受了额外医疗照护。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Opioid use for chronic nonmalignant pain can be harmful. OBJECTIVE: To test whether a multicomponent, group-based, self-management intervention reduced opioid use and improved pain-related disability compared with usual care. DESIGN, SETTING, AND PARTICIPANTS: Multicentered, randomized clinical trial of 608 adults taking strong opioids (buprenorphine, dipipanone, morphine, diamorphine, fentanyl, hydromorphone, methadone, oxycodone, papaveretum, pentazocine, pethidine, tapentadol, and tramadol) to treat chronic nonmalignant pain. The study was conducted in 191 primary care centers in England between May 17, 2017, and January 30, 2019. Final follow-up occurred March 18, 2020. INTERVENTION: Participants were randomized 1:1 to either usual care or 3-day-long group sessions that emphasized skill-based learning and education, supplemented by 1-on-1 support delivered by a nurse and lay person for 12 months. MAIN OUTCOMES AND MEASURES: The 2 primary outcomes were Patient-Reported Outcomes Measurement Information System Pain Interference Short Form 8a (PROMIS-PI-SF-8a) score (T-score range, 40.7-77; 77 indicates worst pain interference; minimal clinically important difference, 3.5) and the proportion of participants who discontinued opioids at 12 months, measured by self-report. RESULTS: Of 608 participants randomized (mean age, 61 years; 362 female [60%]; median daily morphine equivalent dose, 46 mg [IQR, 25 to 79]), 440 (72%) completed 12-month follow-up. There was no statistically significant difference in PROMIS-PI-SF-8a scores between the 2 groups at 12-month follow-up (-4.1 in the intervention and -3.17 in the usual care groups; between-group difference: mean difference, -0.52 [95% CI, -1.94 to 0.89]; P = .15). At 12 months, opioid discontinuation occurred in 65 of 225 participants (29%) in the intervention group and 15 of 208 participants (7%) in the usual care group (odds ratio, 5.55 [95% CI, 2.80 to 10.99]; absolute difference, 21.7% [95% CI, 14.8% to 28.6%]; P < .001). Serious adverse events occurred in 8% (25/305) of the participants in the intervention group and 5% (16/303) of the participants in the usual care group. The most common serious adverse events were gastrointestinal (2% in the intervention group and 0% in the usual care group) and locomotor/musculoskeletal (2% in the intervention group and 1% in the usual care group). Four people (1%) in the intervention group received additional medical care for possible or probable symptoms of opioid withdrawal (shortness of breath, hot flushes, fever and pain, small intestinal bleed, and an overdose suicide attempt). CONCLUSIONS AND RELEVANCE: In people with chronic pain due to nonmalignant causes, compared with usual care, a group-based educational intervention that included group and individual support and skill-based learning significantly reduced patient-reported use of opioids, but had no effect on perceived pain interference with daily life activities. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN49470934.
引用
- Sandhu HK, Booth K, Furlan AD, et al. Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: A Randomized Clinical Trial. JAMA. 2023. PMID: 37219554. doi:10.1001/jama.2023.6454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。